Literature DB >> 15186946

Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries.

Michael G Kinsella1, Colleen Irvin, Michael A Reidy, Thomas N Wight.   

Abstract

Smooth muscle cells (SMC) of the rat carotid arterial media proliferate and migrate in response to injury during the formation of a neointima. The interaction of fibroblast growth factor (FGF-2), which is released at the site of injury, with heparan sulfate proteoglycans (HSPGs) is necessary to induce signaling, which elicits an FGF-dependent mitogenic response by arterial smooth muscle cells, and also serves as a mechanism for storage of the growth factor within the extracellular matrix. However, whether these interactions are critical during neointimal formation has not been directly tested. In this study, a model of FGF-2-dependent medial SMC mitogenic response in balloon-injured rat carotid artery was used to test the effect of degradation of vessel wall heparan sulfate on subsequent SMC proliferation. Treatment of balloon-catheterized rat carotid arteries with chondroitin ABC lyase and/or heparin lyases eliminated heparan sulfates in the vessel wall, as determined by immunoperoxidase staining. In contrast, the distribution in the carotid vessel wall of the large core protein of perlecan, a major vessel wall HSPG that binds FGF-2, is not decreased. The effect of glycosaminoglycan digestion in situ on medial SMC proliferation in response to a bolus injection of FGF-2 after injury was determined by measuring the percentage of SMC nuclei that incorporated 5-bromo-2'-deoxyuridine (BrdU) 48 h after injury. Enzymatic removal of heparan sulfate reduced BrdU incorporation into medial SMC by 60-70% (P < 0.001) at 48 h after injury. Moreover, pre-incubation of FGF-2 with heparin prior to injection restored SMC replication to the levels present in injured vessels treated with buffer alone (P < 0.01). These experiments indicate that endogenous HSPGs are essential to promote FGF-2-driven medial SMC proliferation following injury, and that heparinase treatment can abrogate FGF-2-dependent responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186946     DOI: 10.1016/j.atherosclerosis.2004.01.045

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

1.  Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia.

Authors:  Zhiyong Poon; Dongsook Chang; Xiaoyong Zhao; Paula T Hammond
Journal:  ACS Nano       Date:  2011-04-29       Impact factor: 15.881

2.  ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity.

Authors:  J Dubail; F Kesteloot; C Deroanne; P Motte; V Lambert; J-M Rakic; C Lapière; B Nusgens; A Colige
Journal:  Cell Mol Life Sci       Date:  2010-06-24       Impact factor: 9.261

3.  Molecular weight and concentration of heparin in hyaluronic acid-based matrices modulates growth factor retention kinetics and stem cell fate.

Authors:  Amit K Jha; Anurag Mathur; Felicia L Svedlund; Jianqin Ye; Yerem Yeghiazarians; Kevin E Healy
Journal:  J Control Release       Date:  2015-04-27       Impact factor: 9.776

4.  Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation.

Authors:  Karin Tran-Lundmark; Phan-Kiet Tran; Gabrielle Paulsson-Berne; Vincent Fridén; Raija Soininen; Karl Tryggvason; Thomas N Wight; Michael G Kinsella; Jan Borén; Ulf Hedin
Journal:  Circ Res       Date:  2008-07-03       Impact factor: 17.367

Review 5.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

6.  New Functional Tools for Antithrombogenic Activity Assessment of Live Surface Glycocalyx.

Authors:  Sashka Dimitrievska; Liqiong Gui; Amanda Weyers; Tylee Lin; Chao Cai; Wei Wu; Charles T Tuggle; Sumati Sundaram; Jenna L Balestrini; David Slattery; Lise Tchouta; Themis R Kyriakides; John M Tarbell; Robert J Linhardt; Laura E Niklason
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-07       Impact factor: 8.311

7.  Differential expression of proteoglycans in tissue remodeling and lymphangiogenesis after experimental renal transplantation in rats.

Authors:  Heleen Rienstra; Kirankumar Katta; Johanna W A M Celie; Harry van Goor; Gerjan Navis; Jacob van den Born; Jan-Luuk Hillebrands
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

Review 8.  Therapeutic angiogenesis: controlled delivery of angiogenic factors.

Authors:  Hunghao Chu; Yadong Wang
Journal:  Ther Deliv       Date:  2012-06

9.  Chromosome 2 Fragment Substitutions in Dahl Salt-Sensitive Rats and RNA Sequencing Identified Enpep and Hs2st1 as Vascular Inflammatory Modulators.

Authors:  Olga Berillo; Sofiane Ouerd; Noureddine Idris-Khodja; Asia Rehman; Chantal Richer; Daniel Sinnett; Anne E Kwitek; Pierre Paradis; Ernesto L Schiffrin
Journal:  Hypertension       Date:  2020-11-09       Impact factor: 10.190

10.  Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase.

Authors:  John D Miller; Suzanne E Clabaugh; Deandra R Smith; R Brian Stevens; Lucile E Wrenshall
Journal:  Immunol Cell Biol       Date:  2011-05-24       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.